
    
      An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI,
      formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to
      Ceftazidime Resistant Gram Negative Pathogens
    
  